Crossover Trial of AD109 in Obstructive Sleep Apnea
Status:
Completed
Trial end date:
2021-05-28
Target enrollment:
Participant gender:
Summary
This is a randomized, 4-period, placebo-controlled, crossover, phase 2 clinical study to
examine the efficacy and safety of AD109 versus its individual components or placebo in
patients with obstructive sleep apnea.